They argued that these would only stifle innovation at pharmaceutical firms further more stating that the incentive lies in R&D into medicines which will need significant investments into R&D. With a mutating virus, the developed nations felt that this sort of decisions wouldn't be helpful.  Foreseeable future areas of exploration could attract